Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2 Terminated
1 enrolled 5 charts
Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2 Completed
13 enrolled 14 charts
Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer
Phase 1/2 Completed
28 enrolled 9 charts
LCL161 Plus Topotecan for Patients With Relapsed/Refractory Small Cell Lung Cancer and Select Gynecologic Malignancies
Phase 1 Terminated
34 enrolled
NItCHE-MITO33
Phase 3 Unknown
427 enrolled
MITO23
Phase 3 Completed
242 enrolled
Topotecan, High-Dose Cyclophosphamide, Carboplatin, and an Autologous Peripheral Blood Cell Transplant in Treating Patients With Recurrent Ovarian Cancer or Primary Peritoneal Cancer
Phase 1 Completed
48 enrolled
REBECA
Completed
50 enrolled
Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan
Phase NA Terminated
4 enrolled 8 charts
HECTOR
Phase 3 Completed
550 enrolled
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
Phase 2 Terminated
6 enrolled 7 charts
UCN-01 and Topotecan in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer
Phase 1 Completed
33 enrolled
Sorafenib + Topotecan for Platinum-Resistant Recurrent Ovarian Cancer
Phase 1/2 Terminated
30 enrolled 16 charts
UCN-01 and Topotecan in Treating Patients With Recurrent, Persistent, or Progressive Advanced Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Phase 2 Completed
Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
Phase 1/2 Completed
22 enrolled
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
Phase 2 Completed
40 enrolled 10 charts
Combination Chemotherapy and Autologous Peripheral Stem Cell Transplant in Treating Patients With Stage III, Stage IV, or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
Phase 1 Completed
8 enrolled
Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer
Phase 2 Completed
194 enrolled
Lapatinib and Topotecan in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Did Not Respond to Cisplatin or Carboplatin
Phase 2 Completed
18 enrolled 10 charts
A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
Phase 1 Completed
15 enrolled
Topotecan in Treating Patients With Gynecologic Cancer That Cannot Be Removed by Surgery
Phase 1 Completed
26 enrolled
ITOV04
Phase 1 Terminated
3 enrolled
Combination Chemotherapy in Treating Patients With Advanced Ovarian Epithelial Cancer
Phase 2 Completed
ETC
Phase 1/2 Terminated
3 enrolled
Efficacy Study of Weekly Taxotere and Topotecan for Recurrent Gynecologic (GYN) Cancers
Phase 2 Completed
31 enrolled
Clinical Benefit of Topoisomerase Downregulation
Phase 1 Completed
15 enrolled
Topotecan in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Carcinoma
Phase 1/2 Completed
31 enrolled
Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
Phase 2 Completed
50 enrolled
Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer
Phase 1 Completed
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Ovarian Cancer
Phase 1/2 Completed
50 enrolled
Taxol® in Monotherapy or in Combination With Topotecan or Carboplatin in Patients With Epithelial Ovarian Cancer in Early Relapse
Phase 2 Completed
165 enrolled
Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Phase 2 Completed
Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies
Phase 1 Completed
15 enrolled
Weekly Topotecan Therapy in Patients With Ovarian Cancer
Phase 2 Terminated
32 enrolled
Paclitaxel, Carboplatin, and Topotecan in Patients With Ovarian Cancer
Phase 3 Completed
900 enrolled
Topotecan Vs. Topotecan + Etoposide Vs.Topotecan + Gemcitabine in Ovarian Cancer Therapy
Phase 3 Completed
450 enrolled